1877.HK

Shanghai Junshi Biosciences Co., Ltd. [1877.HK] Stock Forecast

Buy or Sell ? Support and Resistance

What is MACD and how to read it?

How RSI can help?

1877.HK Stock Summary

EPS has been increasing for the past 3 quarters (Quarter statements)

Earnings are expected to fall -100% next year

1877.HK has less than 1 year of cash runway

Top 10 Correlated Stocks

1877.HK

In the News

1877.HK Financial details

Company Rating

Neutral

Market Cap

24.66B

Income

-2.2B

Revenue

1.45B

Book val./share

8.26

Cash/share

4.27

Dividend

Dividend %

Employees

2.57K

Optionable

Shortable

Yes

Earnings

26 Apr 2024

P/E

Forward P/E

PEG

P/S

-216.24

P/B

P/C

2.26

P/FCF

-14.62

Quick Ratio

2.87

Current Ratio

3.43

Debt / Equity

0.13

LT Debt / Equity

0.13

EPS (TTM)

-2.28

EPS next Y

EPS next Q

EPS this Y

242.68%

EPS next Y

EPS next 5Y

EPS last 5Y

18.75%

Revenue last 5Y

334.92%

Revenue Q/Q

-261.55%

EPS Q/Q

-8.7%

SMA20

-9.09%

SMA50

-23.08%

SMA100

-54.55%

Inst Own

Inst Trans

ROA

-16%

ROE

-21%

ROC

-0.2%

Gross Margin

100%

Oper. Margin

1221%

Profit Margin

1162%

Payout

Shs Outstand

Shs Float

Target Price

52W Range

9.47-33.7

52W High

-70.76%

52W Low

+7.22%

RSI

Rel Volume

0.41

Avg Volume

1.27M

Volume

525.27K

Perf Week

-14.15%

Perf Month

-22.43%

Perf Quarter

-46.21%

Perf Half Y

-46.86%

Beta

0.401

Volatility

0.41%, 0.82%

Prev Close

-0.62%

Price

9.65

Change

-0.72%

1877.HK Financial Performance

Yearly Fundamentals Overview

Last date of statement is 2022-12-31

Metric	2018-12-31	2019-12-31	2020-12-31	2021-12-31	2022-12-31
	2.02K	2.02K	2.02K	2.02K	2.02K
Revenue per share	0	1	1.94	4.52	1.58
Net income per share	-1.19	-0.96	-2.03	-0.82	-2.81
Operating cash flow per share	-0.85	-1.52	-1.82	-0.72	-1.94
Free cash flow per share	-1.77	-2.63	-2.54	-1.72	-2.36
Cash per share	4.6	1.56	4.12	4.32	6.54
Book value per share	5.52	3.84	7.11	8.94	10.36
Tangible book value per share	5.52	3.83	7.07	9.3	10.55
Share holders equity per share	5.52	3.84	7.11	8.94	10.36
Interest debt per share	0.95	1.13	1.07	0.73	1.47
Market cap	12.78B	18.56B	38.73B	42.13B	39.3B
Enterprise value	10.59B	18.21B	36.2B	39.25B	34.62B
P/E ratio	-17.84	-24.94	-23.26	-57.86	-15.22
Price to sales ratio	13.69K	23.95	24.29	10.47	27.04
POCF ratio	-25.03	-15.64	-25.84	-65.63	-22.13
PFCF ratio	-11.97	-9.05	-18.52	-27.57	-18.11
P/B Ratio	3.85	6.21	6.63	5.29	4.14
PTB ratio	3.85	6.21	6.63	5.29	4.14
EV to sales	11.34K	23.49	22.7	9.75	23.82
Enterprise value over EBITDA	-16.31	-25.84	-23.7	-92.85	-14.56
EV to operating cash flow	-20.73	-15.34	-24.15	-61.15	-19.5
EV to free cash flow	-9.91	-8.88	-17.31	-25.69	-15.96
Earnings yield	-0.06	-0.04	-0.04	-0.02	-0.07
Free cash flow yield	-0.08	-0.11	-0.05	-0.04	-0.06
Debt to equity	0.17	0.29	0.15	0.08	0.14
Debt to assets	0.13	0.2	0.11	0.06	0.11
Net debt to EBITDA	3.38	0.5	1.66	6.8	1.97
Current ratio	6.18	3.16	3.15	2.89	4.06
Interest coverage	-326.36	-57.48	-57.13	-31.39	-90.96
Income quality	0.71	1.56	0.9	1.08	0.66
Dividend Yield	0	0	0	0	0
Payout ratio	0	-0.08	-0.03	-0.02	-0.01
Sales general and administrative to revenue	133.66	0.32	0.28	0.16	0.4
Research and developement to revenue	576.21	1.22	1.11	0.51	1.64
Intangibles to total assets	0	0	0	0	0.01
Capex to operating cash flow	1.09	0.73	0.4	1.38	0.22
Capex to revenue	-596.76	-1.11	-0.37	-0.22	-0.27
Capex to depreciation	-18.45	-14.48	-3.92	-3.38	-1.34
Stock based compensation to revenue	23.23	0.02	0.02	0.05	0.06
Graham number	12.16	9.09	18	12.83	25.61
ROIC	-0.17	-0.19	-0.25	-0.1	-0.24
Return on tangible assets	-0.17	-0.17	-0.21	-0.07	-0.21
Graham Net	3.09	-0.01	2.29	3.09	4.25
Working capital	2.44B	1.31B	3.21B	3.82B	5.43B
Tangible asset value	3.32B	2.98B	5.81B	8.28B	9.68B
Net current asset value	1.97B	477.19M	2.53B	3.11B	4.42B
Invested capital	0.17	0.29	0.15	0.08	0.14
Average receivables	13.59M	82.12M	413.78M	1.25B	1.18B
Average payables	28.24M	57.4M	82.66M	143.46M	238.9M
Average inventory	39.54M	114.57M	262.05M	414.01M	541.81M
Days sales outstanding	0	77.34	151.8	166.39	130
Days payables outstanding	54.92K	300.33	88.87	56.92	195.3
Days of inventory on hand	66.26K	727.17	336.48	140.58	415.45
Receivables turnover	0	4.72	2.4	2.19	2.81
Payables turnover	0.01	1.22	4.11	6.41	1.87
Inventory turnover	0.01	0.5	1.08	2.6	0.88
ROE	-0.22	-0.25	-0.29	-0.09	-0.27
Capex per share	-0.93	-1.11	-0.72	-1	-0.43

Quarterly Fundamentals Overview

Last date of statement is 2023-09-30 for Q3

Metric	2022-09-30	2022-12-31	2023-03-31	2023-06-30	2023-09-30
	2.02K	2.02K	2.02K	2.02K	2.02K
Revenue per share	-1.04	1.56	0.26	0.42	-0.69
Net income per share	-0.75	-0.85	-0.55	-0.46	-0.42
Operating cash flow per share	-0.73	-0.7	-0.73	-0.51	-0.45
Free cash flow per share	-0.87	-0.82	-0.86	-0.59	-0.86
Cash per share	3.37	6.43	5.48	4.92	4.27
Book value per share	7.21	10.18	9.06	8.62	8.26
Tangible book value per share	7.24	10.38	9.07	8.82	8.16
Share holders equity per share	7.21	10.18	9.06	8.62	8.26
Interest debt per share	0.85	1.42	0.92	1.43	1.07
Market cap	20.56B	39.97B	23.67B	20.8B	15.9B
Enterprise value	17.49B	35.3B	18.65B	17.35B	11.73B
P/E ratio	-7.52	-12.63	-10.89	-11.45	-9.69
Price to sales ratio	-21.73	27.5	92.76	50.17	-23.74
POCF ratio	-31.15	-60.77	-32.86	-41.14	-36.48
PFCF ratio	-25.93	-52.07	-27.98	-35.78	-18.95
P/B Ratio	3.14	4.21	2.64	2.44	1.97
PTB ratio	3.14	4.21	2.64	2.44	1.97
EV to sales	-18.49	24.29	73.1	41.85	-17.52
Enterprise value over EBITDA	-22.39	-38.83	-31	-37.52	-40.27
EV to operating cash flow	-26.5	-53.66	-25.9	-34.32	-26.91
EV to free cash flow	-22.07	-45.98	-22.05	-29.85	-13.98
Earnings yield	-0.03	-0.02	-0.02	-0.02	-0.03
Free cash flow yield	-0.04	-0.02	-0.04	-0.03	-0.05
Debt to equity	0.12	0.14	0.1	0.17	0.13
Debt to assets	0.08	0.11	0.07	0.12	0.09
Net debt to EBITDA	3.92	5.14	8.34	7.46	14.31
Current ratio	2.61	4.06	3.87	3.43	3.13
Interest coverage	0	0	0	0	0
Income quality	0.97	0.83	1.33	1.11	1.06
Dividend Yield	0	0	0	0	0
Payout ratio	-0.01	0	-0.02	-0.02	-0.02
Sales general and administrative to revenue	-0.13	0.11	0.44	0.29	-0.18
Research and developement to revenue	-0.61	0.51	2.07	1.02	-0.48
Intangibles to total assets	0.03	0.01	0.03	0.01	0.03
Capex to operating cash flow	0.2	0.17	0.17	0.15	0.92
Capex to revenue	0.14	-0.08	-0.49	-0.18	0.6
Capex to depreciation	0.97	-0.4	0	-0.52	2.78
Stock based compensation to revenue	0.05	0.06	0	0.04	0.03
Graham number	11.05	13.94	10.59	9.45	8.84
ROIC	-0.11	-0.07	-0.07	-0.06	-0.03
Return on tangible assets	-0.07	-0.06	-0.05	-0.04	-0.04
Graham Net	0.96	4.18	3.11	2.6	1.61
Working capital	2.63B	5.43B	5.03B	4.54B	3.93B
Tangible asset value	6.59B	9.68B	8.96B	8.71B	7.97B
Net current asset value	1.59B	4.42B	3.93B	3.42B	2.53B
Invested capital	0.12	0.14	0.1	0.17	0.13
Average receivables	279.66M	403.63M	408.87M	405.5M	438.28M
Average payables	578.11M	591.04M	669.38M	687.77M	713.07M
Average inventory	538.32M	568.15M	589.63M	616.39M	700.23M
Days sales outstanding	-27.55	32.05	105.85	110.92	-49.14
Days payables outstanding	758.56	256.07	1.11K	141.15	2.06K
Days of inventory on hand	452.6	544.72	610.69	289.3	1.39K
Receivables turnover	-3.27	2.81	0.85	0.81	-1.83
Payables turnover	0.12	0.35	0.08	0.64	0.04
Inventory turnover	0.2	0.17	0.15	0.31	0.06
ROE	-0.1	-0.08	-0.06	-0.05	-0.05
Capex per share	-0.15	-0.12	-0.13	-0.08	-0.41

1877.HK Frequently Asked Questions

What is Shanghai Junshi Biosciences Co., Ltd. stock symbol ?

Shanghai Junshi Biosciences Co., Ltd. is a CN stock and trading under the symbol 1877.HK

What is Shanghai Junshi Biosciences Co., Ltd. stock quote today ?

Shanghai Junshi Biosciences Co., Ltd. stock price is $9.65 today.

Is Shanghai Junshi Biosciences Co., Ltd. stock public?

Yes, Shanghai Junshi Biosciences Co., Ltd. is a publicly traded company.

Something similar

Top by Market Cap

LLY

Company Profile

Volume Average 1.27M
Market Capitalization 24.66B
Employee 2.57K
CEO Mr. Cong Li
Headquarters Shanghai,CN
IPO Date 2018-12-24
Website https://www.junshipharma.com

Shanghai Junshi Biosciences Co., Ltd., a biopharmaceutical company, engages in the discovery, development, and commercialization of various drugs in the therapeutic areas of oncology, metabolic, autoimmune, neurologic, and infectious diseases in the People's Republic of China. The company offers JS001, a recombinant humanized anti-PD-1 monoclonal antibody under the trade name of TUOYI for the indication of melanoma, mucosal melanoma, soft tissue sarcoma, nasopharyngeal carcinoma, urothelial carcinoma, non-small cell lung carcinoma, triple negative breast carcinoma, esophageal squamous cell carcinoma, and hepatocellular carcinoma. It is also developing UBP1211, a biosimilar of Humira for the treatment of rheumatoid arthritis, ankylosing spondylitis, and psoriasis; JS002, a recombinant humanized anti-PCSK9 monoclonal antibody for treating hyperlipidemia; UBP1213, a recombinant humanized anti-BLyS monoclonal antibody for injection. In addition, the company is developing JS501, a biosimilar of Avastin; and JS003, a recombinant humanized anti-PD-L1 monoclonal antibody for injection; JS101, a pan-CDK inhibitor; TAB004/JS004, a recombinant humanized anti-BTLA monoclonal antibody for injection; and JS005, a recombinant humanized anti-IL-17A monoclonal antibody for injection. It has an agreement with Eli Lilly and Company to co-develop therapeutic antibodies for the potential prevention and treatment of COVID-19, the disease caused by the SARS-CoV-2 novel coronavirus as well as Coherus Biosciences, Inc. for the development and commercialization of toripalimab, Junshi Biosciences' anti-PD-1 antibody. Shanghai Junshi Biosciences Co., Ltd. was founded in 2012 and is headquartered in Shanghai, People's Republic of China.